Ultrasound-Activated Prodrugs for Tumor-Specific Immunotherapy

Area of Science:

• Medicinal Chemistry
• Drug Delivery
• Chemical Biology

Background:

• Potent immunotherapeutics require precise spatiotemporal control for activation to minimize systemic toxicity.
• Ultrasound is a safe, deep-penetrating modality, but lacks sensitive chemical triggers for direct activation.
• Existing ultrasound-activated prodrug systems are limited by trigger sensitivity and efficiency.

Purpose of the Study:

• To design and synthesize novel ultrasound-activated prodrugs with enhanced sensitivity and efficiency.
• To establish a structure-activity relationship for ultrasound-responsive benzyloxycarbonyl scaffolds.
• To demonstrate the therapeutic potential of these prodrugs in cancer immunotherapy.

Main Methods:

• Rational design and synthesis of a library of benzyloxycarbonyl-based prodrugs.
• Systematic modulation of electronic properties to control responsiveness to hydroxyl radicals (·OH).
• Density functional theory (DFT) calculations to elucidate activation mechanisms.
• In vivo testing of a BMBC-caged TLR7 agonist in a murine cancer model.

Main Results:

• Identified 3,5-bis(methylamino)-substituted linker (BMBC) as an optimal trigger for rapid drug activation.
• BMBC exhibits enhanced electron-donating character and a minimized activation barrier for radical-mediated release.
• The BMBC platform efficiently cages amines, hydroxyls, and carboxyls, demonstrating broad applicability.
• BMBC-caged TLR7 agonist induced potent antitumor immunity, durable memory, and a widened therapeutic window in vivo.

Conclusions:

• Developed a versatile chemical toolkit for safe and spatiotemporally controlled drug activation using ultrasound.
• BMBC-based prodrugs offer a promising strategy for targeted drug delivery and enhanced cancer immunotherapy.
• This approach significantly improves the safety profile of potent therapeutics by enabling precise activation at the target site.